Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jingyu Yu
Observed name:
Jing-yu Yu
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Shanghai Medical College of Fudan University,
Fudan University,
Huashan Hospital
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Shanghai Medical College of Fudan University,
Fudan University,
Huashan Hospital,
State Key Laboratory of Medical Neurobiology,
Frontiers Center for Brain Science of the Ministry of Education
show all 7
ORCID:
0009-0006-6249-7907
Observed ORCID:
0009-0006-6249-7907
OpenAlex ID:
A5101594099
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2015
·
Julia A. Beaver
, Laleh Amiri-Kordestani
, et al.
·
Clinical Cancer Research
·
401
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
2017
·
Lee Pai-Scherf
, Gideon M. Blumenthal
, et al.
·
The Oncologist
·
312
PDF
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
2017
·
Erin Larkins
, Gideon M. Blumenthal
, et al.
·
The Oncologist
·
228
PDF
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
2020
·
Elaine Chang
, Chana Weinstock
, et al.
·
Clinical Cancer Research
·
201
PDF
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
2020
·
Preeti Narayan
, Tatiana M. Prowell
, et al.
·
Clinical Cancer Research
·
195
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation–Associated Advanced Ovarian Cancer
2017
·
Sanjeeve Balasubramaniam
, Julia A. Beaver
, et al.
·
Clinical Cancer Research
·
191
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
2021
·
Preeti Narayan
, Christy L. Osgood
, et al.
·
Clinical Cancer Research
·
190
PDF
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
2017
·
Hongshan Li
, Jingyu Yu
, et al.
·
Journal of Pharmacokinetics and Pharmacodynamics
·
153
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
2018
·
Gwynn Ison
, Lynn J. Howie
, et al.
·
Clinical Cancer Research
·
145
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
2023
·
Asma Dilawari
, Mirat Shah
, et al.
·
Clinical Cancer Research
·
142
PDF
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib
2016
·
Erin Larkins
, Gideon M. Blumenthal
, et al.
·
Clinical Cancer Research
·
142
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
2018
·
Anand Shah
, Erik Bloomquist
, et al.
·
Clinical Cancer Research
·
129
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
2018
·
Harpreet Singh
, Amanda J. Walker
, et al.
·
Clinical Cancer Research
·
109
PDF
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
2017
·
Meredith K. Chuk
, Jennie T. Chang
, et al.
·
Clinical Cancer Research
·
96
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer
2020
·
Mirat Shah
, Suparna Wedam
, et al.
·
Clinical Cancer Research
·
73
PDF
Gene Therapy Strategies Targeting Aging-Related Diseases
2022
·
Jingyu Yu
, Tianwen Li
, et al.
·
Aging and Disease
·
70
PDF
Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling
2019
·
Youwei Bi
, Jiang Liu
, et al.
·
The Journal of Clinical Pharmacology
·
64
FDA Approval Summary: TAS-102
2017
·
Leigh Marcus
, Steven J. Lemery
, et al.
·
Clinical Cancer Research
·
60
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
2016
·
Harpreet Singh
, Michael Brave
, et al.
·
Clinical Cancer Research
·
58
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
2020
·
Jennifer J. Gao
, Christy L. Osgood
, et al.
·
Clinical Cancer Research
·
54
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
2024
·
Michael H. Brave
, William F. Maguire
, et al.
·
Clinical Cancer Research
·
49
PDF
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer
2025
·
Melanie Royce
, Mirat Shah
, et al.
·
Clinical Cancer Research
·
46
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
2021
·
Melanie Royce
, Christy L. Osgood
, et al.
·
Clinical Cancer Research
·
44
Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing Tool
2023
·
Tianwen Li
, Liansheng Zhang
, et al.
·
Advanced Science
·
42
Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non–Small Cell Lung Cancer
2018
·
Hongshan Li
, Yaning Sun
, et al.
·
Journal of Pharmaceutical Sciences
·
36
PDF
Show more works
View as search
Works count:
61
Citation count:
3,336
H-index:
26
I10-index:
28
Year
Topic
Type